Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply
The Lancet Haematology
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626002243?dgcid=rss_sd_all
Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626002243?dgcid=rss_sd_all
“Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply.” The Lancet Haematology.
@article{article68598,
title = {Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626002243?dgcid=rss_sd_all}
}